Australia markets closed

Willow Biosciences Inc. (3D7.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.0600-0.0060 (-9.09%)
At close: 08:02AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in CAD. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
949
1,172
821
133
10
Operating expenses
Research development
5,816
6,800
7,473
11,511
7,257
Selling general and administrative
4,447
6,018
9,102
8,604
6,417
Total operating expenses
11,994
14,649
19,221
23,307
16,856
Operating income or loss
-11,045
-13,477
-18,400
-23,174
-16,846
Interest expense
-
142
26
27
40
Total other income/expenses net
449
318
3,365
16,647
-17,215
Income before tax
-10,620
-13,034
-14,761
-6,140
-33,946
Income tax expense
-3
-5
53
0
0
Income from continuing operations
-10,617
-13,029
-14,814
-6,140
-33,946
Net income
-10,617
-13,029
-14,814
-6,140
-33,946
Net income available to common shareholders
-10,617
-13,029
-14,814
-6,140
-33,946
Basic EPS
-0.13
-0.10
-0.12
-0.05
-0.41
Diluted EPS
-0.13
-0.10
-0.12
-0.05
-0.41
Basic average shares
124,043
124,243
123,660
119,988
81,994
Diluted average shares
124,043
124,243
123,660
119,988
81,994